Ponatinib in refractory Philadelphia chromosome-positive leukemias Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Fusion Proteins, bcr-abl
  • Imidazoles
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma
  • Protein-Tyrosine Kinases
  • Pyridazines

abstract

  • Ponatinib was highly active in heavily pretreated patients with Ph-positive leukemias with resistance to tyrosine kinase inhibitors, including patients with the BCR-ABL T315I mutation, other mutations, or no mutations. (Funded by Ariad Pharmaceuticals and others; ClinicalTrials.gov number, NCT00660920.).

publication date

  • November 29, 2012

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3777383

Digital Object Identifier (DOI)

  • 10.1056/NEJMoa1205127

PubMed ID

  • 23190221

Additional Document Info

start page

  • 2075

end page

  • 88

volume

  • 367

number

  • 22